Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor
申请人:Recordati S.A., Chemical and Pharmaceutical Company
公开号:US20020183290A1
公开(公告)日:2002-12-05
Described are derivatives with an adrenergic antagonistic activity and, in particular, high selectivity for &agr;
1a
- and &agr;
1d
-adrenergic receptors compared to &agr;
1b
-receptors. This selectivity profile suggests the use of these derivatives in the treatment of symptoms of the lower urinary tract, including those associated to benign prostatic hyperplasia, without the side effects associated with hypotensive activity.
描述了具有肾上腺素拮抗活性的衍生物,特别是相对于α1b-受体具有较高选择性的α1a-和α1d-肾上腺素受体。这种选择性配置表明这些衍生物可用于治疗下尿路症状,包括与良性前列腺增生相关的症状,而不会出现与降压活性相关的副作用。